Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: The Company is a Cayman Islands blank check company (SPAC) incorporated on May 23, 2024, intended to effect a business combination with one or more businesses, primarily in the pharmaceutical industry. As of the reporting date, the Company had not commenced any operations. All activity relates to formation, the Initial Public Offering (IPO), and identifying a target.
Capital Structure: The Company consummated its IPO on January 29, 2025, selling 20,000,000 Units. On February 18, 2025, underwriters exercised the full over-allotment option for an additional 3,000,000 Units. Simultaneously, the Sponsor purchased Private Placement Units.
Key Financial Metrics
| Metric | Value (Sep 30, 2025) | Value (Dec 31, 2024) |
|---|---|---|
| Cash and Cash Equivalents | $717 | $1,351 |
| Trust Account Balance | $237,604,232 | $0 |
| Total Assets | $237,632,428 | $550,824 |
| Total Liabilities | $7,356,611 | $795,669 |
| Shareholders' Deficit | $(7,328,415) | $(244,845) |
| Working Capital | $(428,415) | $(790,678) |
Operating Results (Nine Months Ended Sep 30, 2025):
- Net Income: $5,727,685
- Interest Income (Trust Account): $6,454,232
- General and Administrative Costs: $726,547
- Net Income Per Share (Basic/Diluted): $0.19
Debt and Liquidity:
- Deferred Underwriting Fee: $6,900,000 (payable only upon completion of a business combination).
- Promissory Note (Related Party): $0 outstanding (fully repaid).
- Share Subscription Receivable: $608,822 (amount due from Sponsor for Private Placement Units).
Material Changes vs. Prior Period
- Trust Account Funding: The most significant change is the funding of the Trust Account with $231,150,000 following the IPO and over-allotment exercise in early 2025. This balance grew to $237.6 million due to interest earnings.
- Revenue Generation: The Company transitioned from a pre-IPO entity with no assets to a post-IPO entity generating significant non-operating income ($6.45M) solely from interest on Trust Account investments.
- Liabilities: Total liabilities increased to $7.36 million, primarily driven by the recognition of the $6.9 million deferred underwriting fee and accrued offering costs.
- Equity Classification: 23,000,000 Public Shares are now classified as temporary equity (subject to redemption) valued at $237.6 million, whereas no such shares existed at year-end 2024.
Outlook, Risks, and Management Commentary
Business Combination Timeline: The Company has until April 29, 2026 (15 months from IPO) to complete a business combination. This period can be extended twice by three months each (total 21 months) if the Sponsor deposits $0.10 per share into the Trust Account for each extension.
Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern within one year due to the mandatory liquidation date if a business combination is not completed. The financial statements do not include adjustments that might result from this uncertainty.
Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses including inadequate segregation of duties and insufficient written policies.
Risks:
- Geopolitical Instability: Risks associated with the Russia-Ukraine and Israel-Hamas conflicts could impact global markets and the ability to find a target.
- Cybersecurity: As a blank check company relying on third-party digital technologies, the Company faces potential cybersecurity threats with limited internal resources to mitigate them.
- Liquidity: The Company has minimal operating cash ($717) and relies on the Sponsor for working capital loans or the Trust Account interest to fund operations until a combination is consummated.
Investor Verification Checklist
- Trust Account Yield: Verify the current interest rate environment and its impact on the Trust Account balance, which directly affects the redemption value per share (currently approx. $10.33).
- Extension Terms: Confirm the Sponsor's financial capacity to fund the $0.10 per share extension payments if the 15-month deadline is not met.
- Internal Control Remediation: Review subsequent filings to determine if the material weaknesses in internal controls (segregation of duties, written policies) have been remediated.
- Share Subscription Receivable: Monitor the collection of the $608,822 receivable from the Sponsor to ensure full funding of the Private Placement Units.
- Target Identification: Assess the progress of the Company in identifying a pharmaceutical target, given the 15-month deadline to close a deal.